Yahoo Finance

Addex to Present at the Swiss Biotech Day 2024

Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that ...
FierceBiotech

Addex's eyelid data fail to make clear case for spasm expansion

Addex Therapeutics’ attempt to expand use of dipraglurant into muscle spasms has stumbled at the first hurdle. A phase 2a clinical trial of the mGluR5 negative allosteric modulator has delivered ...

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease modelsContinued ...
Business Insider

Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Geneva, Switzerland, April 21, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
manilatimes

Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders

Geneva, Switzerland - June 30, 2025 - Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...
Yahoo Finance

Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference

Geneva, Switzerland, June 5, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...
FierceBiotech

Trial site staff shortages, sluggish patient recruitment force Addex to scrap phase 3 Parkinson's study

Addex Therapeutics waited more than a decade for the chance to learn whether dipraglurant is effective in dyskinesia associated with Parkinson’s disease (PD-LID), suffering delay after delay as it ...
Seeking Alpha

Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration

Geneva, Switzerland, December 8, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today ...
Yahoo

Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients

GENEVA--(Marketwire - Nov 5, 2012) - Addex Therapeutics / Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients. Processed and transmitted by ...
Seeking Alpha

Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric ...
Nasdaq

Addex Expands Pipeline with Selective M4 Positive Allosteric Modulator Program for the Treatment of Schizophrenia & Other Psychotic Disorders

Geneva, Switzerland, April 6, 2022-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, ...